S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
Log in
NASDAQ:TXG

10x Genomics Stock Forecast, Price & News

$179.67
-0.22 (-0.12 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$175.45
Now: $179.67
$184.17
50-Day Range
$140.25
MA: $150.56
$179.89
52-Week Range
$48.78
Now: $179.67
$184.17
Volume550,774 shs
Average Volume1.04 million shs
Market Capitalization$18.03 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. Its company offers chromium instruments, enzymes, microfluidic chips, slides, reagents, and other consumable products. The company's single cell solution runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics, including the physical organization of DNA; single cell CNV for measuring cellular heterogeneity through DNA changes, such as copy number variation; and visium spatial gene expression solution that measures the spatial gene expression patterns across a tissue sample. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10X Genomics, Inc. in November 2014. 10x Genomics, Inc. was founded in 2012 and is headquartered in Pleasanton, California.

MarketRank

Overall MarketRank

1.20 out of 5 stars

Analyst Opinion: 1.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TXG
CUSIPN/A
CIKN/A
Phone925 401 7300
Employees584

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$245.89 million
Book Value$4.36 per share

Profitability

Net Income$-31,250,000.00

Miscellaneous

Market Cap$18.03 billion
Next Earnings Date2/16/2021 (Estimated)
OptionableOptionable
$179.67
-0.22 (-0.12 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TXG News and Ratings via Email

Sign-up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











10x Genomics (NASDAQ:TXG) Frequently Asked Questions

How has 10x Genomics' stock price been impacted by COVID-19?

10x Genomics' stock was trading at $60.76 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TXG shares have increased by 195.7% and is now trading at $179.67.
View which stocks have been most impacted by COVID-19
.

Is 10x Genomics a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" 10x Genomics stock.
View analyst ratings for 10x Genomics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than 10x Genomics?

Wall Street analysts have given 10x Genomics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but 10x Genomics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is 10x Genomics' next earnings date?

10x Genomics is scheduled to release its next quarterly earnings announcement on Tuesday, February 16th 2021.
View our earnings forecast for 10x Genomics
.

How were 10x Genomics' earnings last quarter?

10x Genomics, Inc. (NASDAQ:TXG) released its quarterly earnings results on Tuesday, November, 10th. The company reported ($0.33) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.33). The business earned $71.82 million during the quarter, compared to analyst estimates of $62.71 million. 10x Genomics had a negative return on equity of 19.18% and a negative net margin of 31.06%.
View 10x Genomics' earnings history
.

What price target have analysts set for TXG?

8 brokerages have issued 1 year target prices for 10x Genomics' shares. Their forecasts range from $85.00 to $195.00. On average, they anticipate 10x Genomics' share price to reach $134.90 in the next year. This suggests that the stock has a possible downside of 24.9%.
View analysts' price targets for 10x Genomics
or view Wall Street analyst' top-rated stocks.

Who are some of 10x Genomics' key competitors?

Who are 10x Genomics' key executives?

10x Genomics' management team includes the following people:
  • Dr. Serge Saxonov Ph.D., Co-Founder, CEO & Director (Age 44, Pay $551.25k)
  • Dr. Benjamin J. Hindson Ph.D., Co-Founder, Pres, Chief Scientific Officer & Director (Age 46, Pay $426.51k)
  • Mr. Justin J. McAnear, Chief Financial Officer (Age 46, Pay $399.75k)
  • Mr. Eric S. Whitaker, Gen. Counsel (Age 54, Pay $416.74k)
  • Mr. Paul W. Wyatt, VP of Operations
  • Mr. Jonathan Schimmel, VP of Global Support & Sales Operations
  • Mr. Sam Ropp, Sr. VP of Global Sales
  • Mr. Edwin Hauw, VP of Marketing
  • Ms. Jean M. Philibert, Chief People Officer (Age 61)
  • Mr. Michael Schnall-Levin, Sr. VP of R&D & Founding Scientist

When did 10x Genomics IPO?

(TXG) raised $297 million in an initial public offering (IPO) on Thursday, September 12th 2019. The company issued 9,000,000 shares at a price of $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen was co-manager.

What is 10x Genomics' stock symbol?

10x Genomics trades on the NASDAQ under the ticker symbol "TXG."

Who are 10x Genomics' major shareholders?

10x Genomics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Hamilton Lane Advisors LLC (0.08%) and IFM Investors Pty Ltd (0.01%). Company insiders that own 10x Genomics stock include Associates Vi LP Venrock, Benjamin J Hindson, Bryan E Roberts, Foresite Capital Fund I, LP, Foresite Capital Management I,, John R Stuelpnagel, Justin J Mcanear and Serge Saxonov.
View institutional ownership trends for 10x Genomics
.

Which major investors are buying 10x Genomics stock?

TXG stock was purchased by a variety of institutional investors in the last quarter, including Hamilton Lane Advisors LLC, and IFM Investors Pty Ltd. Company insiders that have bought 10x Genomics stock in the last two years include Bryan E Roberts, and Foresite Capital Fund I, LP.
View insider buying and selling activity for 10x Genomics
or or view top insider-buying stocks.

How do I buy shares of 10x Genomics?

Shares of TXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is 10x Genomics' stock price today?

One share of TXG stock can currently be purchased for approximately $179.67.

How big of a company is 10x Genomics?

10x Genomics has a market capitalization of $18.03 billion and generates $245.89 million in revenue each year. The company earns $-31,250,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. 10x Genomics employs 584 workers across the globe.

What is 10x Genomics' official website?

The official website for 10x Genomics is www.10xgenomics.com.

How can I contact 10x Genomics?

10x Genomics' mailing address is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. The company can be reached via phone at 925 401 7300 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.